ORGANOVO

Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company's lead molecule, FXR314, is on the path for Phase 2 investigation in inflammatory bowel disease and has potential application in metabolic disease and oncology. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease... Organovo creates human models of inflammatory bowel disease (IBD) using our 3D tissue technologies and uses them to understand, invent, and develop the best drug therapies for ulcerative colitis and Crohn's disease. We believe that drugs discovered through this method have a greater chance to show benefit in clinical trials... The Investor Relations website contains information about Organovo Holdings, Inc.'s business for stockholders, potential investors, and..

Also known as: Organovo Holdings, Organovo Holdings, Inc., Organovo, Inc.

Primary location: San Diego United States